Delving into the Latest Updates on Arrow Pharmaceuticals Pty Ltd. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

H2 receptor(组胺H2受体)	1

关联

1

项与 Arrow Pharmaceuticals Pty Ltd. 相关的药物

Nizatidine

尼扎替丁

靶点

H2 receptor

作用机制

H2 receptor拮抗剂

在研机构

Arrow Pharmaceuticals Pty Ltd.初创企业 [+2]

原研机构

Eli Lilly & Co.

在研适应症

糜烂性食管炎 [+6]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1988-04-12

1

项与 Arrow Pharmaceuticals Pty Ltd. 相关的临床试验

CTRI/2012/04/002607 / Not yet recruitingN/A

A multicenter, open label, randomized, balanced, two treatment, three period, three sequence, reference replicate crossover, single dose, bioequivalence study of Capecitabine Tablets, USP 500mg manufactured by Amneal Pharmaceuticals, USA and XELODAÂ® (Capecitabine) Tablets 500mg distributed by Genentech USA, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080-4990, following a single oral 2000mg (4x500mg) dose administration in adult human cancer patients under fed condition.

开始日期2012-05-01

申办/合作机构

Amneal Pharmaceuticals Pty Ltd.

100 项与 Arrow Pharmaceuticals Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Arrow Pharmaceuticals Pty Ltd. 相关的专利（医药）

登录后查看更多信息

2

项与 Arrow Pharmaceuticals Pty Ltd. 相关的文献（医药）

2022-05-03·Neurology

A Phase 3 Trial of IPX203 vs CD-LD IR in Parkinson’s Disease Patients with Motor Fluctuations (RISE-PD) (S16.010)

作者: LeWitt, Peter ; Stocchi, Fabrizio ; Ellenbogen, Aaron ; Espay, Alberto J. ; Isaacson, Stuart ; Hauser, Robert A. ; Pahwa, Rajesh ; D’Souza, Richard ; Visser, Hester

2022-05-03·Neurology

Duration of Benefit Per Dose: Post Hoc Analysis of “Good On” Time Per Dose for IPX203 vs CD-LD IR in the RISE-PD Phase 3 Trial (P10-11.002)